Christopher M Jones1, Melinda Campopiano1, Grant Baldwin1, Elinore McCance-Katz1. 1. Christopher M. Jones is with the Office of Public Health Strategy and Analysis, Office of the Commissioner, Food and Drug Administration, Silver Spring, MD. Melinda Campopiano is with the Division of Pharmacologic Therapies, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, Rockville, MD. Grant Baldwin is with the Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA. Elinore McCance-Katz is with the Office of Policy, Planning, and Innovation, Substance Abuse and Mental Health Services Administration.
Abstract
OBJECTIVES: We estimated national and state trends in opioid agonist medication-assisted treatment (OA-MAT) need and capacity to identify gaps and inform policy decisions. METHODS: We generated national and state rates of past-year opioid abuse or dependence, maximum potential buprenorphine treatment capacity, number of patients receiving methadone from opioid treatment programs (OTPs), and the percentage of OTPs operating at 80% capacity or more using Substance Abuse and Mental Health Services Administration data. RESULTS: Nationally, in 2012, the rate of opioid abuse or dependence was 891.8 per 100 000 people aged 12 years or older compared with national rates of maximum potential buprenorphine treatment capacity and patients receiving methadone in OTPs of, respectively, 420.3 and 119.9. Among states and the District of Columbia, 96% had opioid abuse or dependence rates higher than their buprenorphine treatment capacity rates; 37% had a gap of at least 5 per 1000 people. Thirty-eight states (77.6%) reported at least 75% of their OTPs were operating at 80% capacity or more. CONCLUSIONS: Significant gaps between treatment need and capacity exist at the state and national levels. Strategies to increase the number of OA-MAT providers are needed.
OBJECTIVES: We estimated national and state trends in opioid agonist medication-assisted treatment (OA-MAT) need and capacity to identify gaps and inform policy decisions. METHODS: We generated national and state rates of past-year opioid abuse or dependence, maximum potential buprenorphine treatment capacity, number of patients receiving methadone from opioid treatment programs (OTPs), and the percentage of OTPs operating at 80% capacity or more using Substance Abuse and Mental Health Services Administration data. RESULTS: Nationally, in 2012, the rate of opioid abuse or dependence was 891.8 per 100 000 people aged 12 years or older compared with national rates of maximum potential buprenorphine treatment capacity and patients receiving methadone in OTPs of, respectively, 420.3 and 119.9. Among states and the District of Columbia, 96% had opioid abuse or dependence rates higher than their buprenorphine treatment capacity rates; 37% had a gap of at least 5 per 1000 people. Thirty-eight states (77.6%) reported at least 75% of their OTPs were operating at 80% capacity or more. CONCLUSIONS: Significant gaps between treatment need and capacity exist at the state and national levels. Strategies to increase the number of OA-MAT providers are needed.
Authors: Erin M Johnson; William A Lanier; Ray M Merrill; Jacob Crook; Christina A Porucznik; Robert T Rolfs; Brian Sauer Journal: J Gen Intern Med Date: 2012-10-16 Impact factor: 5.128
Authors: Nancy L Sohler; Linda Weiss; James E Egan; Carolina M López; Jamie Favaro; Robert Cordero; Chinazo O Cunningham Journal: J Opioid Manag Date: 2013 Mar-Apr
Authors: John D Scott; Kent T Unruh; Mary C Catlin; Joseph O Merrill; David J Tauben; Roger Rosenblatt; Dedra Buchwald; Ardith Doorenbos; Cara Towle; Christian B Ramers; David H Spacha Journal: J Telemed Telecare Date: 2012-12-03 Impact factor: 6.184
Authors: Jon E Zibbell; Rachel Hart-Malloy; John Barry; Lillian Fan; Colleen Flanigan Journal: Am J Public Health Date: 2014-09-11 Impact factor: 9.308
Authors: Bradley D Stein; Adam J Gordon; Andrew W Dick; Rachel M Burns; Rosalie Liccardo Pacula; Carrie M Farmer; Douglas L Leslie; Mark Sorbero Journal: J Subst Abuse Treat Date: 2014-08-02
Authors: Erin L Winstanley; Laura R Lander; James H Berry; James J Mahoney; Wanhong Zheng; Jeremy Herschler; Patrick Marshalek; Sheena Sayres; Jay Mason; Marc W Haut Journal: J Subst Abuse Treat Date: 2019-05-08
Authors: Kimberly D Brunisholz; Andrew J Knighton; Amulya Sharma; Lisa Nichols; Kristen Reisig; Jed Burton; Debbie Scovill; Carolyn Tometich; Mark Foote; Shelly Read; Scott Whittle Journal: Prog Community Health Partnersh Date: 2020
Authors: Jennifer Miles; Jason Howell; Dave Sheridan; George Braucht; Amy Mericle Journal: Am J Drug Alcohol Abuse Date: 2020-02-24 Impact factor: 3.829